How worrying is the Delta variant? Is there a digital health bubble? And what is going on at the FDA?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the latest twists following the FDA’s widely condemned decision to approve Aduhelm, Biogen’s treatment for Alzheimer’s disease. Then, our STAT colleague Helen Branswell joins us to talk about whether viral variants are going to stymie the U.S.’s summer reopening. Finally, STAT’s Mario Aguilar calls in to break down the record-setting sums going into digital health companies in 2021.
For more on what we cover, here’s the latest on Aduhelm; here’s more from Helen; here’s the news in digital health; here’s the 2021 STAT Breakthrough Science Summit; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
Create a display name to comment
This name will appear with your comment